Abstract: Gastric cancer (GC) is one of the most common digestive tract malignancies in the world with most patients being initially diagnosed as having advanced gastric cancer (AGC). The clinical effects of routine chemotherapy in these patients are limited and more effective therapeutic targets and biomarkers require further investigation. DLC1 is a universally known tumor suppressor gene, inhibiting tumorigenesis and tumor progression in digestive tract malignancies and has been found to be downregulated in liver, gastric, colorectal, and esophageal cancers among many other types of solid cancers. Previous studies have shown that DLC1 is not only related to epigenetic modifications, apoptosis, autophagy, microbial infection, and microsatellite instability, but it also significantly impacts the occurrence and development of gastric cancer, as well as the therapeutic efficacy and prognosis in such patients. In this review, the structure and function of DLC1 and its role in the occurrence, development, and treatment of gastric cancer are discussed in detail, to aid future research.